Author Bio
Matt is a Certified Financial Planner based in South Carolina who has been writing for The Motley Fool since 2012. Matt specializes in writing about bank stocks, REITs, and personal finance, but he loves any investment at the right price. Follow him on Twitter to keep up with his latest work!
Follow @TMFMathGuy
Progyny (NASDAQ:PGNY) is a recent healthcare IPO that aims to revolutionize the fertility industry. And with a market cap of just over $4 billion, it could still have a long way to grow in a huge market that s just begging to be disrupted. In this Jan. 7
This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Progyny, the fertility benefits provider, struggled in the first part of 2020 when many fertility clinics closed and business fell roughly 85%, CEO David Schlanger told Business Insider.
The company rebounded well towards the end of the year as clinics reopened and more patients resumed treatment.
Now, the company is dusting off its shelved growth strategy and is actively evaluating potential acquisition targets, Schlanger said.
Like many Americans, fertility benefits provider Progyny is dusting off its 2020 goals, many of which were sidelined at the onset of the coronavirus pandemic, heading into the new year.